May 1, 2026 — 8:30 AM Los Angeles News Desk Update.

Summit Therapeutics filed its Q1 2026 Form 10-Q with the SEC at 5:00 PM Eastern on April 30, 2026 — one hour after the market close that began Bob Duggan’s worst 24 hours as a public-company principal. By 11:06 AM Eastern this morning, SMMT was trading at $16.65, down 22.41% on the session, with a day low of $15.20 already printed on volume of 8.7 million shares.

The 10-Q explains why. Scroll down the bottom to read the SMMT 10Q.

The Going Concern Disclosure

Three separate sections of the filing — the financial statement notes, the Liquidity section of Management’s Discussion and Analysis, and Item 1A Risk Factors — contain the same conclusion in nearly identical language: “These conditions raise substantial doubt about our ability to continue as a going concern.”

Item 1A presents this as a standalone risk factor heading in italics: “We do not currently have sufficient working capital to fund our planned operations for the next twelve months. There is uncertainty regarding our ability to raise additional capital and as such, there is substantial doubt regarding our ability to continue as a going concern.”

This is not boilerplate. “Substantial doubt about ability to continue as a going concern” is a defined accounting standard under ASC 205-40 that requires disclosure when a company’s own auditors and management conclude that liquid resources are insufficient to fund 12 months of planned operations from the date the financial statements are issued.

Summit’s Q1 numbers tell the story. Cash and equivalents at March 31, 2026: $106.5 million. Short-term investments: $492.2 million. Total liquid resources: $598.7 million. Q1 net cash used in operating activities: $122.3 million — meaning Summit burned approximately $40 million per month in the quarter just ended. Research and development expenses for Q1 2026 were $132.6 million, up 158% from $51.3 million in Q1 2025, with management explicitly stating it expects R&D to continue increasing as HARMONi-3, HARMONi-7, and HARMONi-GI3 enrollment progresses.

At current burn, Summit has approximately twelve months of runway. At the trajectory R&D is on, less. The company’s auditors required the going-concern disclosure to be made.

The $4.56 Billion Akeso Milestone Overhang

Page 33 of the 10-Q documents the contingent obligations sitting underneath Summit’s ivonescimab program. In addition to payments already made to Chinese partner Akeso, “there are additional potential milestone payments of $4.56 billion, as Akeso will be eligible to receive regulatory milestones of up to $1.05 billion and commercial milestones of up to $3.51 billion. In addition, Akeso will be eligible to receive low double-digit royalties on net sales.”

Summit’s total stockholders’ equity at March 31, 2026: $545.9 million. Accumulated deficit: $2.48 billion. The company holds $4.56 billion in contingent milestone obligations to a Chinese counterparty against a balance sheet smaller than the milestones themselves.

This produces a perverse risk structure for shareholders. If ivonescimab succeeds, it triggers payment obligations Summit cannot fund from current resources. The success case requires additional dilutive capital raises. The failure case ends the company. There is no scenario in the current capital structure where shareholders avoid further dilution.

The April 21 Forecast Confirmed

On April 21, 2026, the Scientology Money Project published OT8 Bob Duggan: Summit Therapeutics UK Strike Off Notice — What Does It Signal?, documenting the London Gazette First Notice initiating compulsory dissolution of Summit (Oxford) Limited — the operational R&D subsidiary that had failed to file its January 25, 2026 confirmation statement. That investigation laid out the eight-subsidiary, five-jurisdiction architecture: a Delaware parent at 70%+ Duggan ownership, two Delaware operating entities, a Cayman Islands holdco of undescribed function, three UK entities (one entering dissolution, one with no active program, one a vestigial UK plc remnant), a Swiss GmbH with no disclosed facility, and an Irish Limited whose Dublin address corresponds to a serviced-office provider rather than a research facility.

Our April 21 piece also documented the Q2 2025 Type III modification: 44,488,976 performance-based stock options accelerated by a Compensation Committee that, under Summit’s controlled-company exemption, is not required to be entirely independent. The total compensation benefit recognized through the modification approached $851 million, with no cash paid and no performance gating retained.

The April 30 10-Q confirms every element of the architecture and adds the going-concern disclosure that the architecture was always pointing toward. The same filing that documents the going-concern condition discloses that R&D expense for Q1 2026 included $24.4 million of stock-based compensation, with $41.4 million more flowing through G&A — and that as of March 31, 2026, $166.4 million of unrecognized compensation cost from the Type III modification remained to be expensed over the next 1.4 years.

Translation: while the auditors are signing off on substantial doubt about the company’s ability to fund twelve months of operations, the executive compensation tail from the Q2 2025 modification continues to accrue against the income statement at a rate exceeding the Q1 cash burn. The architecture I described on April 21 — controlled-company governance, three-person CODM, undescribed offshore entities, Type III acceleration, UK subsidiary wind-down — is the architecture in which the going-concern disclosure was prepared, signed by Duggan, Zanganeh, and Soni, and filed at 5:00 PM Eastern yesterday. The market read it overnight and confirmed it at the open.

The HARMONi-3 Interim That Wasn’t

The clinical disclosure that triggered the institutional reanalysis appears on page 31. Patient enrollment completed for the squamous cohort of HARMONi-3 in Q1 2026. Summit had previously announced an interim PFS analysis for Q2 2026 that the market understood as a potential early efficacy signal capable of supporting accelerated FDA engagement.

The 10-Q discloses that the interim analysis happened. The Independent Data Monitoring Committee recommended the study continue as planned. No safety concerns were noted. The study continues double-blinded. The previously guided timing of the final PFS analysis in H2 2026 is unchanged.

In Phase 3 oncology development, an “uneventful” iDMC recommendation on an early interim PFS analysis is read as the absence of an early efficacy signal strong enough to justify accelerated regulatory engagement. It is a soft negative read on the asset. The market pushed the meaningful catalyst out to H2 2026 and repriced accordingly.

The Insider PIPE Now Underwater

Page 13 documents the October 21, 2025 private placement at $18.74 per share. Co-CEO and Executive Chairman Robert W. Duggan, Co-CEO and President Mahkam Zanganeh, COO and CFO Manmeet Soni, the CAO, “and certain non-executive employees and other related persons” purchased an aggregate of 14,514,402 shares for approximately $272 million. Akeso purchased an additional 533,617 shares for $10 million. Outside biotech institutional investors put in $218 million.

Today’s $15.20 day low and last night’s $15.80 after-hours trough place SMMT 16-19% below the price at which Duggan and the entire C-suite committed personal capital six months ago. The insider PIPE is now meaningfully underwater in cash terms. At my $12 target — a price the stock has not yet printed but is structurally consistent with the disclosed risk picture — the insider position would sit 36% below cost.

The Janssen Federal Case That Isn’t in the 10-Q

Item 1 of Part II, Legal Proceedings, occupies one page of the filing. It discloses the Rainaldi Revocable Trust derivative lawsuit filed March 17, 2025 in the Delaware Court of Chancery, which seeks rescission of the shares Duggan and Zanganeh received as prepaid interest on the December 2022 Notes. It discloses a European Patent Office opposition against the in-licensed EP3882275B1 patent covering ivonescimab.

It does not disclose Janssen Global Services, LLC v. Nwachukwu, Case No. 3:26-CV-02563-MAS-TJB, filed in the United States District Court for the District of New Jersey on March 12, 2026. It does not disclose Janssen’s March 27, 2026 Rule 26(d) motion for expedited discovery, which I have published in this investigation.

The Janssen complaint and the expedited-discovery brief explicitly name Summit Therapeutics as a venue where the alleged misappropriation of “highly sensitive Company documents” and “proprietary and trade secret information” — approximately 7,185 files allegedly downloaded by Cynthia Nwachukwu before her resignation from Janssen — may be in active commercial use. The Rule 26(d) motion seeks depositions and document production specifically about Nwachukwu’s responsibilities and activities at Summit.

Both filings predate Summit’s quarterly reporting period close on March 31, 2026. The 10-Q was signed by Manmeet Soni as Principal Financial Officer and certified by Duggan and Zanganeh as Principal Executive Officers on April 30, 2026 — forty-nine days after the federal complaint, thirty-four days after the Rule 26(d) motion.

Summit’s position appears to be that Janssen v. Nwachukwu names a Summit employee but not Summit itself, and therefore does not require disclosure under Item 103 of Regulation S-K. That position is contestable. When a federal complaint and an expedited-discovery motion explicitly identify a public company as a venue where allegedly misappropriated trade secrets may be in commercial use, and seek discovery into that company’s operations, the reasonably foreseeable material liability standard arguably triggers disclosure.

The omission is itself a potential securities exposure. Plaintiffs in any subsequent securities-fraud action would point to the 10-Q’s silence on a federal trade-secrets matter that names the company throughout the pleadings.

The Rainaldi Suit Moves Forward

While the Janssen exposure goes undisclosed, the disclosed Rainaldi derivative action is now substantively moving. The Delaware Supreme Court issued its ruling on the constitutional questions that had stayed the Rainaldi briefing on February 27, 2026. The briefing schedule for the defendants’ motion to dismiss was filed with the courts on April 16, 2026.

The underlying allegations concern the December 2022 Notes — $520 million in unsecured bridge financing Duggan and Zanganeh issued to themselves to fund the Akeso license. The Rainaldi Revocable Trust alleges breach of fiduciary duty and unjust enrichment, and seeks rescission of the shares Duggan and Zanganeh received as prepaid interest under those notes. Prepaid interest was paid in shares valued at $0.7913 per share.

A Delaware Chancery court is now on a path to substantively examine whether Duggan and Zanganeh enriched themselves through the bridge-financing structure that funded Summit’s foundational asset acquisition. If the plaintiffs prevail on the rescission remedy, Duggan loses shares.

The Donations He Cannot Reach

Bob Duggan has donated an estimated >$400 million to the Church of Scientology over his Scientology career. He could use that money now. Scientology has a strict no-return-of-donations policy that is formalized in a contract parishioners sign.

That sum is approximately equivalent to the Q1 2026 R&D budget multiplied by three. It is approximately equivalent to two-thirds of Summit’s current liquid resources. It is approximately equivalent to the entire principal of the original $400 million December 2022 promissory note Duggan issued to himself to fund the Akeso transaction.

The OT8 who built the financial architecture is bound by the contractual architecture of the organization he funded.

The Strategic Trap

Reading the 10-Q against the after-hours and morning trading action, the structural picture is clear. Duggan is operating Summit Therapeutics under simultaneous pressure on every available exit:

He cannot issue more shares and dilute on attractive terms. The going-concern disclosure plus the $4.56 billion Akeso milestone overhang plus the undisclosed Janssen exposure means any institutional buyer in a follow-on offering demands a steep discount or refuses to participate. The October 2025 PIPE at $18.74 is now the high-water mark, not the floor.

He cannot sell the company. Janssen v. Nwachukwu names Summit throughout the pleadings as a venue where allegedly misappropriated trade secrets may be in commercial use. No strategic acquirer will assume that contingent liability without full discovery and indemnification carve-outs that would materially reduce any sale price.

He cannot ride it out indefinitely. The going-concern disclosure puts a twelve-month clock on operations at the current burn rate, with R&D expenses trending higher.

He cannot reach the $400 million he has given to Scientology over decades.

The market made its decision overnight and confirmed it at the open. The 10-Q explains why. The next disclosure cycle will reveal whether Summit’s omission of Janssen v. Nwachukwu from Item 103 was a defensible interpretation or a material misstatement.

Stock-based Compensation is the Tell

The screenshot from SMMT 10Q posted below shows that total segment expenses tripled. Q1 2026 at $195.2 million versus Q1 2025 at $66.9 million. That is a 192% year-over-year increase in operating expenses at a company with zero revenue. No commercial-stage biotech runs that kind of expense ramp. No development-stage biotech either, unless something is being forced through the system:

Stock-based compensation is the tell. $72.8M in Q1 2026 versus $11.1M in Q1 2025 — up 556%.

Here’s what the segment table makes visible that the income statement obscures. Stock-based compensation is now the largest single segment expense at Summit Therapeutics. Larger than oncology clinical trial costs. Larger than cash compensation. Larger than all other expenses combined. A development-stage biotech with one licensed asset, going-concern qualification, and four parallel Phase 3 trials is recognizing more cost from accelerated executive equity vesting than from running the trials themselves.

That’s not a sustainable expense structure. It’s the accounting consequence of the Q2 2025 Compensation Committee decision flowing through the income statement at the worst possible time.

Cash compensation is also up materially. $26.4M versus $15.9M, up 66%. Summit was hiring through Q1 2026 — the 10-Q references continued executive team building and additional clinical, regulatory, and scientific personnel. That hiring continued into and through the quarter that ended with going-concern qualification. Either the executive team did not anticipate the going-concern condition when they were hiring (which would suggest a planning failure) or they did anticipate it and hired anyway (which would suggest the spending was strategic — building the commercial infrastructure ivonescimab would need if HARMONi-3 had delivered the early efficacy signal).

The “Other expenses” line at $5.8M versus $3.5M — up 64% — is the G&A tail outside of compensation. Legal fees, professional services, the Wilson Sonsini relationship Mr. Clark sits on, the various property and lease arrangements with Maky Zanganeh and Associates and Duggan’s affiliates. That category grew faster than revenue (which is to say, it grew while revenue remained zero).

About This Investigation

I have published the underlying federal court filings in Janssen Global Services, LLC v. Cynthia Nwachukwu, Case No. 3:26-CV-02563-MAS-TJB (D.N.J.), in a prior article in this series. Summit Therapeutics’ Q1 2026 Form 10-Q is filed with the SEC under CIK 0001599298 and is publicly available on EDGAR.

The April 30, 2026 10Q